When will the patents on NYSTATIN-TRIAMCINOLONE ACETONIDE expire, and when will generic NYSTATIN-TRIAMCINOLONE ACETONIDE be available?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmaderm	NYSTATIN-TRIAMCINOLONE ACETONIDE	nystatin; triamcinolone acetonide	OINTMENT;TOPICAL	062603-001	Oct 9, 1985		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 17, 2026

Nystatin-triamcinolone acetonide is a combination antifungal and corticosteroid medication. Its primary therapeutic role is in treating superficial fungal infections of the skin, particularly those complicated by inflammation. The drug's efficacy stems from nystatin's fungicidal action against various yeasts, primarily Candida species, and triamcinolone acetonide's potent anti-inflammatory, antipruritic, and vasoconstrictive properties. This dual action addresses both the causative pathogen and the symptomatic inflammation, offering relief for conditions such as intertrigo, diaper rash, and fungal dermatitis.

WHAT IS THE CURRENT PATENT STATUS FOR NYSTATIN-TRIAMCINOLONE ACETONIDE?

The patent landscape for nystatin-triamcinolone acetonide is largely characterized by the expiration of original composition-of-matter patents for both active pharmaceutical ingredients (APIs). Nystatin, a polyene macrolide antibiotic produced by Streptomyces noursei, was discovered in the 1950s. Triamcinolone acetonide, a synthetic corticosteroid, was developed in the late 1950s and early 1960s.

The initial patents covering these individual molecules have long since expired. Consequently, generic manufacturers have been able to produce and market these APIs. The patent protection for the combination product itself typically revolves around specific formulations, manufacturing processes, or novel delivery systems.

A review of patent databases indicates that broad composition-of-matter patents for nystatin and triamcinolone acetonide expired several decades ago. For instance, patents covering the initial isolation and synthesis of nystatin would have expired by the mid-1970s to early 1980s. Similarly, patents for triamcinolone acetonide would have followed a similar expiration timeline.

Patents that might still be relevant are those related to:

Specific Formulations: These could cover unique topical bases (creams, ointments, lotions), particle sizes of the APIs, or excipient combinations designed to enhance stability, penetration, or patient compliance. For example, a patent might claim a cream formulation with a specific emulsifier system that improves the dispersion of both nystatin and triamcinolone acetonide.
Manufacturing Processes: Patents can be granted for novel or improved methods of manufacturing the combination drug. This could include specific synthesis routes for either API that are more efficient or produce higher purity, or methods for combining the APIs into the final dosage form that offer advantages.
Method of Use Patents: While less common for established drug combinations, a patent could theoretically exist for a new or improved therapeutic use of nystatin-triamcinolone acetonide for a specific indication or patient population, provided it demonstrates novelty and non-obviousness. However, for a combination treating common dermatological conditions, such patents are unlikely to be granted without significant new findings.

Example Patent Expiration Analysis:

Nystatin (Original Composition): Discovered in the 1950s. Assumed patent term of 17 years from grant. Likely expired by the mid-1970s.
Triamcinolone Acetonide (Original Composition): Developed in the late 1950s/early 1960s. Assumed patent term of 17 years from grant. Likely expired by the mid-1970s to early 1980s.
Potential Formulation Patents: These would be granted based on application dates. A patent filed in 2000 with a 20-year term would expire in 2020. Newer formulation patents could exist.

A search of the United States Patent and Trademark Office (USPTO) and European Patent Office (EPO) databases reveals numerous patents related to nystatin and triamcinolone acetonide, but the vast majority pertain to specific formulations or production methods rather than the core molecules. Patents claiming specific combinations or formulations are often filed by originator companies to extend market exclusivity around a particular product. However, the breadth of these formulation patents is critical. Many are likely expired or soon to expire, opening the door for generic competition.

WHAT ARE THE KEY CLINICAL AND MARKET INDICATIONS FOR NYSTATIN-TRIAMCINOLONE ACETONIDE?

Nystatin-triamcinolone acetonide is indicated for the topical treatment of superficial fungal infections of the skin where inflammation is a significant component. The primary indications include:

Cutaneous Candidiasis: Infections caused by Candida albicans and other Candida species, such as intertrigo, paronychia, and fungal dermatitis.
Inflammatory Dermatoses with Secondary Fungal Infection: Conditions like eczema, psoriasis, or allergic dermatitis that become secondarily infected with fungi. The corticosteroid component reduces inflammation, itching, and redness, while the antifungal component eradicates the fungal pathogen.
Diaper Dermatitis: Particularly when complicated by a Candida yeast infection.
Tinea (Ringworm) Infections: In some cases, when inflammation is prominent and a fungal infection is suspected or confirmed.

The market for topical corticosteroids and antifungals is mature and highly competitive. Nystatin-triamcinolone acetonide competes with a wide array of products, including:

Other combination antifungal-corticosteroid products: e.g., clotrimazole-betamethasone, miconazole-hydrocortisone.
Monotherapy antifungal agents: e.g., clotrimazole, miconazole, terbinafine.
Monotherapy corticosteroid agents: e.g., hydrocortisone, triamcinolone acetonide (alone), betamethasone.
Newer generation antifungal agents: e.g., efinaconazole, tavaborole.

The market is largely driven by prescription, although some lower-potency combinations are available over-the-counter. The key drivers for prescription include physician preference, patient response, cost, and insurance formulary placement. The presence of a potent corticosteroid like triamcinolone acetonide positions this combination for conditions requiring significant anti-inflammatory action, distinguishing it from products with milder corticosteroids or those solely focused on antifungal treatment.

WHAT ARE THE FUNDAMENTAL COMMERCIAL VIABILITY CONSIDERATIONS FOR INVESTING IN NYSTATIN-TRIAMCINOLONE ACETONIDE PRODUCTS?

The commercial viability of investing in nystatin-triamcinolone acetonide products hinges on several critical factors, primarily related to the patent exclusivity, manufacturing costs, market competition, and regulatory pathways.

Intellectual Property Landscape and Generic Competition

Expired Core Patents: As noted, patents for the individual APIs, nystatin and triamcinolone acetonide, have long expired. This fundamental fact means that the cost of goods for API synthesis is driven by competitive generic manufacturing, primarily from Asia.
Formulation Patents: The primary opportunity for patent-protected market exclusivity lies in novel or improved formulations. Companies that hold patents on unique topical delivery systems, improved stability, enhanced skin penetration, or specific combinations of excipients that offer a distinct clinical advantage may have a period of market exclusivity. However, the expiry of these formulation patents will inevitably lead to generic entry.
Patent Cliffs: The "patent cliff" is a significant risk. If current market exclusivity for a branded nystatin-triamcinolone acetonide product is tied to formulation patents nearing expiry, a substantial decline in revenue can be anticipated upon the entry of generic competitors.
Abbreviated New Drug Application (ANDA) Landscape: The pathway for generic drug approval in the U.S. is via an ANDA. The number of ANDAs filed and approved for nystatin-triamcinolone acetonide products is a key indicator of impending generic competition. A high number of approved ANDAs suggests intense price competition in the near future.

Manufacturing and Supply Chain

Cost of Goods Sold (COGS): With expired API patents, the primary cost drivers are raw material sourcing (for excipients), API procurement (from generic suppliers), manufacturing (compounding, filling, packaging), and quality control. Companies with efficient manufacturing processes and strong supplier relationships can achieve lower COGS.
API Sourcing: Reliance on a limited number of API suppliers can create supply chain risks. Diversification of API sources, potentially across different geographic regions, is advisable.
Formulation Complexity: The choice of formulation (ointment, cream, lotion) impacts manufacturing complexity and cost. Ointments are typically simpler to manufacture than complex creams or lotions requiring specific emulsion technologies.
Scale of Operations: Larger-scale manufacturing operations generally benefit from economies of scale, reducing per-unit production costs.

Market Dynamics and Competition

Therapeutic Indication Dominance: Nystatin-triamcinolone acetonide is not a first-line treatment for all fungal infections. Its utility is greatest where inflammation is a prominent feature. The size and growth rate of this specific niche within the broader dermatology market are crucial.
Competition with Monotherapies and Other Combinations: The drug faces competition from simpler antifungal monotherapies (which may be sufficient for less inflammatory cases) and other antifungal-corticosteroid combinations with different API profiles (e.g., different corticosteroids or antifungals). Market share will depend on clinical differentiation, physician preference, and cost-effectiveness.
Prescriber Behavior: Physician prescribing habits are influenced by clinical trial data, past experience, educational initiatives, and formulary restrictions. Understanding these drivers is vital.
Payer Reimbursement: Insurance companies (payers) play a significant role. They establish formularies, set reimbursement rates, and may favor certain products based on cost-effectiveness or therapeutic equivalence. The drug's inclusion on key formularies is a critical success factor.
Over-the-Counter (OTC) vs. Prescription: While primarily prescription, potential for OTC availability of lower-potency versions of similar combinations can impact the market. However, the potency of triamcinolone acetonide generally limits its OTC accessibility.

Regulatory and Clinical Considerations

Bioequivalence: For generic products seeking FDA approval, demonstrating bioequivalence to a reference listed drug is paramount. This involves proving that the generic product performs comparably to the branded product in the body, typically through in vitro dissolution testing or in vivo pharmacokinetic studies.
Stability and Shelf-Life: Ensuring the stability of the combined APIs in the chosen formulation over the product's shelf-life is a critical regulatory requirement and a potential area for formulation patent protection.
Safety Profile: While both APIs are well-established, the safety profile of the combination, particularly concerning potential side effects of the corticosteroid (e.g., skin thinning, striae, acneiform eruptions) with long-term or widespread use, is important.

Investment Scenarios

Generic Manufacturer: Investing in a generic manufacturing company with established capabilities in topical product development and ANDA filings for nystatin-triamcinolone acetonide. Success depends on efficient manufacturing, strong distribution networks, and aggressive pricing strategies. The profit margin will be compressed due to competition.
Specialty Pharma Focused on Formulation Improvement: Investing in a company developing novel or improved formulations of existing drugs, including nystatin-triamcinolone acetonide. This strategy relies on securing new patents for these improved formulations, thereby extending market exclusivity beyond the original patent expiry. This requires significant R&D investment and a robust patent strategy.
Contract Manufacturing Organization (CMO): Investing in a CMO that specializes in topical drug manufacturing. Such a company would benefit from increased demand for generic nystatin-triamcinolone acetonide products as patents expire and brand manufacturers face competition.

The overall commercial viability is moderate to high for companies that can efficiently produce generic versions or develop patented, improved formulations in a competitive landscape. The lack of novel API innovation means the market will likely be characterized by price-based competition once generic entry is widespread.

WHAT ARE THE KEY RISKS AND REWARDS ASSOCIATED WITH INVESTING IN NYSTATIN-TRIAMCINOLONE ACETONIDE?

Key Risks

Intense Generic Competition: The most significant risk is the high probability of widespread generic competition. Once formulation patents expire, multiple manufacturers can enter the market, leading to rapid price erosion and reduced profit margins for both branded and generic players. This can drastically reduce the return on investment for any product based on expired or soon-to-expire patents.
Price Volatility: The pharmaceutical market, especially for established generic drugs, is subject to significant price fluctuations. Payer negotiations, competitive bidding, and market dynamics can lead to unpredictable pricing.
Limited Differentiation for Generic Products: For generic manufacturers, differentiation is minimal beyond price and market access. Product quality and reliability are table stakes. Any perceived advantage is often short-lived.
Formulation Patent Challenges: Companies holding formulation patents may face legal challenges from generic competitors seeking to invalidate these patents, potentially leading to earlier-than-expected generic entry.
Supply Chain Vulnerabilities: Reliance on a few API suppliers, particularly those in regions with geopolitical instability or regulatory scrutiny, can lead to supply disruptions and increased costs. The quality and consistency of generic API suppliers are also a concern.
Regulatory Hurdles: While existing APIs have established safety profiles, any new formulation or manufacturing process must undergo rigorous regulatory review. Delays or rejections by regulatory bodies like the FDA can impact market entry timelines and profitability.
Market Saturation: The topical antifungal and corticosteroid market is already saturated with numerous products. Gaining significant market share against established players requires substantial marketing and sales efforts, which can be costly.
Therapeutic Obsolescence: While unlikely for such a basic combination, the emergence of significantly superior treatments for inflammatory fungal infections could eventually reduce the demand for nystatin-triamcinolone acetonide.

Key Rewards

Established Market Demand: Nystatin-triamcinolone acetonide treats common dermatological conditions with significant patient populations. The demand for effective, affordable treatments for these conditions is consistent and substantial.
Cost-Effective Treatment: For generic manufacturers, the ability to produce and market an affordable version of this combination drug offers a reliable revenue stream, particularly if distributed effectively. This is especially true for healthcare systems and patients seeking lower-cost alternatives.
Opportunities in Emerging Markets: As healthcare access expands in emerging economies, there is a growing demand for established, cost-effective medications like nystatin-triamcinolone acetonide. Generic manufacturers can capitalize on these markets with appropriate pricing and distribution strategies.
Potential for Formulation Innovation: Companies capable of developing and patenting novel formulations that offer improved efficacy, patient convenience, or reduced side effects could secure a period of market exclusivity and command premium pricing. Examples include enhanced delivery systems that improve API penetration or a formulation with a better cosmetic feel.
Leveraging Existing Manufacturing Infrastructure: For companies already involved in topical pharmaceutical manufacturing, introducing nystatin-triamcinolone acetonide can leverage existing production lines and expertise, minimizing initial capital investment.
Portfolio Diversification: For a pharmaceutical company, adding nystatin-triamcinolone acetonide to its portfolio, particularly within dermatology, can offer diversification and strengthen its market presence.
Predictable Regulatory Pathway (for Generics): The regulatory pathway for generic drugs (ANDA) is well-defined. While demanding, it offers a clear path to market entry for companies meeting the established standards for bioequivalence and manufacturing quality.

The rewards are primarily tied to efficient generic manufacturing and distribution, or to successful innovation in formulation patents that create a temporary market advantage. The risks are heavily weighted towards intense competition and price erosion.

KEY TAKEAWAYS

Nystatin-triamcinolone acetonide is a well-established topical medication for inflammatory fungal infections. Its commercial future is defined by the expiry of core API patents, leading to a highly competitive generic market. Investment opportunities lie in efficient generic manufacturing and distribution, or in developing patented, improved formulations that extend market exclusivity.

FREQUENTLY ASKED QUESTIONS

What is the primary therapeutic advantage of combining nystatin with triamcinolone acetonide? The combination addresses both the fungal infection (via nystatin) and the associated inflammation, itching, and redness (via triamcinolone acetonide), providing a more comprehensive treatment for conditions where both are present.
Are there any active patents that currently prevent generic entry of nystatin-triamcinolone acetonide? Broad composition-of-matter patents for nystatin and triamcinolone acetonide have expired. Generic entry may be delayed only by the existence of active patents covering specific formulations, manufacturing processes, or methods of use, which vary by product and region.
What are the main cost drivers for producing generic nystatin-triamcinolone acetonide products? The primary cost drivers include the procurement of generic active pharmaceutical ingredients (nystatin and triamcinolone acetonide), excipients for the formulation, manufacturing processes (compounding, filling, packaging), quality control, and distribution.
How does the competitive landscape for nystatin-triamcinolone acetonide products compare to other topical antifungal or corticosteroid medications? The landscape is highly competitive, similar to many topical dermatological agents. It competes against monotherapies (antifungal or corticosteroid alone), other combination products with different API profiles, and potentially newer agents. The key differentiator for this specific combination is the balance of a broad-spectrum antifungal with a potent corticosteroid for inflamed conditions.
What are the most significant risks for a company investing in the manufacturing of nystatin-triamcinolone acetonide? The most significant risks are intense generic competition leading to rapid price erosion, potential supply chain vulnerabilities for API sourcing, and the challenges of differentiating a generic product in a saturated market beyond price.

CITATIONS

[1] National Library of Medicine. (n.d.). Nystatin. LiverTox: Clinical and Toxicological Effects of Pharmaceutical Agents. Retrieved from https://livertox.nih.gov/Nystatin.htm

[2] National Library of Medicine. (n.d.). Triamcinolone. LiverTox: Clinical and Toxicological Effects of Pharmaceutical Agents. Retrieved from https://livertox.nih.gov/Triamcinolone.htm

[3] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs) for Generic Drugs. Retrieved from https://www.fda.gov/drugs/types-of-drug-applications/abbreviated-new-drug-applications-andas-generic-drugs

[4] U.S. Patent and Trademark Office. (n.d.). Patent Basics. Retrieved from https://www.uspto.gov/learning-and-resources/patent-and-trademark-resource-center/patent-basics

[5] European Patent Office. (n.d.). About the EPO. Retrieved from https://www.epo.org/about-us.html

NYSTATIN-TRIAMCINOLONE ACETONIDE Drug Patent Profile

Which patents cover Nystatin-triamcinolone Acetonide, and when can generic versions of Nystatin-triamcinolone Acetonide launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nystatin-triamcinolone Acetonide

AI Deep Research

Questions you can ask:

Summary for NYSTATIN-TRIAMCINOLONE ACETONIDE

US Patents and Regulatory Information for NYSTATIN-TRIAMCINOLONE ACETONIDE

NYSTATIN-TRIAMCINOLONE ACETONIDE: PATENT LANDSCAPE AND COMMERCIAL VIABILITY